167 related articles for article (PubMed ID: 14569947)
41. Acupuncture to reduce nausea during chemotherapy treatment of rheumatic diseases.
Josefson A; Kreuter M
Rheumatology (Oxford); 2003 Oct; 42(10):1149-54. PubMed ID: 12777644
[TBL] [Abstract][Full Text] [Related]
42. Oral ondansetron: a useful addition to the supportive care armamentarium?
Hesketh PJ
Am J Clin Oncol; 1994 Apr; 17(2):147-9. PubMed ID: 8141106
[No Abstract] [Full Text] [Related]
43. Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer.
Borgeat A; Wilder-Smith O; Forni M; Suter PM
Can J Anaesth; 1994 Nov; 41(11):1117-9. PubMed ID: 7828261
[TBL] [Abstract][Full Text] [Related]
44. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V
Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
[TBL] [Abstract][Full Text] [Related]
45. Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide.
Meden H; Meissner O; Conrad A; Kuhn W
Eur J Gynaecol Oncol; 1996; 17(2):114-22. PubMed ID: 8654467
[TBL] [Abstract][Full Text] [Related]
46. Survey ranking of emetogenic control in children receiving chemotherapy.
Small BE; Holdsworth MT; Raisch DW; Winter SS
J Pediatr Hematol Oncol; 2000; 22(2):125-32. PubMed ID: 10779025
[TBL] [Abstract][Full Text] [Related]
47. [Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma].
Hou M; Li L; Qiu M; Yan X; Zhu J; Gou HF
Ai Zheng; 2005 Apr; 24(4):461-4. PubMed ID: 15820070
[TBL] [Abstract][Full Text] [Related]
48. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
[TBL] [Abstract][Full Text] [Related]
49. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
50. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
51. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
Lordick F; Ehlken B; Ihbe-Heffinger A; Berger K; Krobot KJ; Pellissier J; Davies G; Deuson R
Eur J Cancer; 2007 Jan; 43(2):299-307. PubMed ID: 17134890
[TBL] [Abstract][Full Text] [Related]
52. [Efficiency of using ondansetron in the surgical treatment of post-burn cicatricial deformity in children with a history of postoperative nausea and vomiting].
Lekmanov AU; Tkachenko BA; Suvorov SG
Anesteziol Reanimatol; 2008; (1):21-3. PubMed ID: 18368834
[TBL] [Abstract][Full Text] [Related]
53. [Effects of Nasea on prevention of gastrointestinal side effects caused by chemotherapeutic drugs].
Xie XD; Zheng ZD; Liu DW; Liu YY; Shan XJ
Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(13):1180-2. PubMed ID: 12921641
[TBL] [Abstract][Full Text] [Related]
54. [Clinical evaluation of ondansetron suppository].
Kobayashi F; Yamanouchi T; Shimizu T; Sato H; Adachi I; Sakamoto T; Fujimaki M; Horikoshi I
Gan To Kagaku Ryoho; 1997 Mar; 24(5):625-7. PubMed ID: 9087300
[No Abstract] [Full Text] [Related]
55. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
[TBL] [Abstract][Full Text] [Related]
56. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
[TBL] [Abstract][Full Text] [Related]
57. [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets].
Sasaki K; Yanagida T; Ohya M; Ishikawa H
Gan To Kagaku Ryoho; 2000 Mar; 27(3):443-9. PubMed ID: 10740639
[TBL] [Abstract][Full Text] [Related]
58. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
Bonadonna G; Viviani S; Bonfante V; Gianni AM; Valagussa P
Eur J Cancer; 2005 May; 41(7):998-1006. PubMed ID: 15862748
[TBL] [Abstract][Full Text] [Related]
59. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:
Italian Group For Antiemetic Research
J Clin Oncol; 2004 Feb; 22(4):725-9. PubMed ID: 14966097
[TBL] [Abstract][Full Text] [Related]
60. Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery.
Krobbuaban B; Pitakpol S; Diregpoke S
J Med Assoc Thai; 2008 May; 91(5):669-74. PubMed ID: 18672630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
